This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Curis Appoints Ali Fattaey, Ph.D. As President And Chief Operating Officer

- Brings Over 20 Years of Experience in Cancer Research, Drug Discovery and Development, Including Nexavar ® (sorafenib) and PD-0332991 (palbociclib) -

LEXINGTON, Mass., Feb. 19, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced the appointment of Ali Fattaey, Ph.D., as President and Chief Operating Officer. Dr. Fattaey will join Curis' senior management team, where he will help guide and further advance Curis' overall corporate strategic goals and will also be responsible for the oversight and implementation of the Company's research and development operations. Dan Passeri will continue to serve as Chief Executive Officer and Michael Gray will continue to serve as Chief Financial Officer.

Dr. Fattaey has held leadership positions at several cancer-focused organizations and brings significant research and development experience to Curis, including eight years at Onyx Pharmaceuticals, Inc., where he was responsible for multiple programs in partnership with Pfizer, Inc. (then Parke-Davis/Warner-Lambert) and Bayer HealthCare, which led to the discovery and development of Nexavar ® (sorafenib), now approved by the FDA for the treatment of advanced renal cell carcinoma and unresectable hepatocellular cancer. In addition, Dr. Fattaey led the discovery of palbociclib, a small molecule selective inhibitor of the CDK 4 and 6 kinases, now in late stage clinical development for treatment of advanced breast cancer.

"We are extremely pleased to have Ali join the Curis senior management team," said Dan Passeri, Chief Executive Officer of Curis. "He brings extensive experience and knowledge of targeted cancer treatment to guide our growth into a leading oncology drug company. We believe that Ali's impressive background will enable us to continue building and advancing our pipeline of novel drug candidates, including our IAP inhibitor CUDC-427 and our dual PI3K and HDAC inhibitor CUDC-907."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.91 +93.33 0.53%
S&P 500 2,081.34 +12.58 0.61%
NASDAQ 4,997.4590 +5.5190 0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs